Biogen has unveiled plans to spin off its hemophilia business as an independent, publicly traded company. The new company will build upon the strength of current therapies for hemophilia A and B while Biogen will focus on therapies for neurology. “We expect that the new company will be a leader in discovering, developing, and commercializing innovative therapies for hemophilia, built on remarkable science and a deep understanding of how to continually improve treatment for patients,” said Geo...